Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Solid Tumors
NCT04616248Phase 1Active, not recruiting
- Sponsor
- University of Southern California
- Start
- Jan 2023
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CDX-1140 in solid tumor, melanoma, squamous cell carcinoma (SCC) and 4 more (2 cohorts), sponsored by University of Southern California. Primary endpoints: Incidence of adverse events at 30 days and Maximum tolerated dose or maximum administered dose at 30 days. Started Jan 2023; status: active, not recruiting.
02
Drugs
CDX-1140
03
Conditions
solid tumormelanomasquamous cell carcinoma (SCC)basal cell carcinoma (BCC)Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT04616248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616248.